Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib: Sub-Study of the SENSCIS Trial — Francesco Bonella (2021) | RDL Network
Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib: Sub-Study of the SENSCIS Trial
Article 2021 en
Authors
FB
Francesco Bonella
SH
Steve E. Humphries
ÉH
É. Hachulla
Abstract
1 min read
Introduction: In the SENSCIS trial with SSc-ILD, nintedanib (NIN) reduced the rate of decline in FVC (mL/year) over 52 weeks by 44% vs. placebo. The effects of NIN on markers of lung damage on HRCT were assessed in a sub-study.
S.M. Humphries, Dinesh Khanna, Totaro Takeuchi, Michael R Hamblin, Dag Wormanns, C. Ittrich, F. Risse, Susanne Stowasser, Martina Gahlemann, David A. Lynch
Trishul Siddharthan, Suzanne L. Pollard, Peter Jackson, Nicole Robertson, Adaeze C. Wosu, Nihaal Rahman, Roma Padalkar, Isaac Sekitoleko, Esther Namazzi, Patricia Alupo, John R. Hurst, Robert Kalyesubula, David W. Dowdy, Robert A. Wise, Peter J Barnes, William Checkley, Bruce Kirenga
Graham Devereux, Seonaidh Cotton, Shona Fielding, Nicola McMeekin, Peter J Barnes, Andrew Briggs, Graham Burns, Rekha Chaudhuri, Henry Chrystyn, Lisa Davies, Anthony De Soyza, Simon Gompertz, John Haughney, Karen Innes, Joanna Kaniewska, Amanda Lee, Alyn H. Morice, John Norrie, A. Sullivan, Andrew M. Wilson, David Price
Seung Yong Shin, Sang Jin Han, Jin Seok Kim, Sung Il Im, Jaemin Shim, Jinhee Ahn, Eun Mi Lee, Yae Min Park, Jun Hyung Kim, Professor Gregory Lip, Hong Euy Lim
Discussion(0)
No comments yet. Be the first to comment.